HOXA9 and acute myeloid leukemia: Entospletinib was an inhibitor of SYK, and AML patients with higher HOXA9/MEIS1 expression had improved overall survival than lower HOXA9/MEIS1 expression, when patients received entospletinib in combination with intensive chemotherapy in a phase Ib/II study (63).